RevMed earns standing ovation at ASCO for pancreatic cancer data while Akeso faces caution

At the American Society of Clinical Oncology meeting, RevMed captured audience attention with data on its pancreatic cancer therapy, earning a rare standing ovation.

In contrast, presentations from Akeso and Summit fell short of expectations, prompting caution among attendees.

The conference also highlighted a novel immunotherapy approach, though details were limited in the brief report.